Antimicrobial Vascular Access Technology

Company Background

Trinity Vascular Technologies is a medical device company advancing next-generation antimicrobial vascular access technologies.

Trinity Vascular Technologies was spun out of ACatechol to commercialize a patented triple-action zwitterionic surface technology—well established and clinically proven—now engineered for polyurethane vascular access devices, supported by anticipated regulatory clearance and strong patent protection.

Since 2020, the platform has been supported by competitive federal research funding from the National Institutes of Health (NIH), the National Science Foundation (NSF), and the U.S. Department of Defense (DoD), along with private research support totaling several million dollars.

Over multiple years of development, Trinity has demonstrated proof of concept through in vitro and in vivo studies, validating performance (80% reduction in infection) and safety in preventing vascular access device–associated infections, including CLABSI.

With foundational research completed, Trinity is now advancing toward U.S. regulatory clearance and commercialization.

Strategic & Institutional Alignment

Trinity is advancing commercialization through collaboration and alignment with academic and industry stakeholders, including:

Clinical development collaboration with leading academic medical centers
Distribution strategy alignment with national GPO networks
Strategic engagement with vascular access device partners

Supported by Competitive Federal Research Funding

Strategic & Clinical Collaborations